Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

NCT04164082 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04164082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04164082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 18, 2020
Completion date
December 9, 2026
Enrollment
161 (estimated)
Sites
390

Conditions

As the registry lists them; a condition with its own page is linked.

bladder flat urothelial carcinoma in situ, non-muscle invasive bladder urothelial carcinoma, stage 0a bladder cancer ajcc v8, stage 0is bladder cancer ajcc v8, stage i bladder cancer ajcc v8